This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Lung Cancer
  • /
  • Treatment of ALK-rearranged non-small-cell lung ca...

Treatment of ALK-rearranged non-small-cell lung cancer with brigatinib as second or later lines: real-world observations from a single institution.

Read time: 1 mins
Published:1st Aug 2019
Author: Hochmair M, Weinlinger C, Schwab S, Naber J, Setinek U, Krenbek D et al.
Availability: Pay for access, or by subscription
Ref.:Anticancer Drugs. 2019;30(7):e0787.
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest